Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.
Explore this paper's citation graph
Summary
Results suggest that in a group of patients with active systemic sclerosis, low-dose MTX seems to be more effective than placebo according to pre-defined response criteria.
- Type
- article
- Published
- 1996-04-01
- Cited by
- 330
- References
- 36
- Access
- Open access
- OpenAlex
- https://openalex.org/W2149183272
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:37369882
Keywords
Medicine, Placebo, Methotrexate, DLCO, Internal medicine
References
- A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis.
- Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
- Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients.
- Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy.
- Prediction of creatinine clearance from serum creatinine.
- Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine.
- A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma.
- Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients.
- D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.
- Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.
- Recombinant interferon-gamma in the treatment of systemic sclerosis.
- A COMPUTER‐ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS
- Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.
- Intra-arterially administered reserpine and saline in scleroderma.
- A new promising treatment in systemic sclerosis: 5-fluorouracil.
- Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis.
- Predictors of survival in systemic sclerosis (scleroderma).
- 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.
- Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial.
- Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.
Cited by
- Practical approach to the therapy of systemic slcerosis
- Pathogenesis of systemic sclerosis—current concept and emerging treatments
- Systemic sclerosis: Current concepts of skin and systemic manifestations.
- Nailfold Videocapillaroscopy as a Candidate Biomarker for Organ Involvement and Prognosis in Patients with Systemic Sclerosis
- Use of methotrexate in patients with scleroderma and mixed connective tissue disease.
- Stem cells: HSCT for systemic sclerosis—swallows and summers
- Current management strategies for systemic sclerosis.
- Anti-inflammatory and immunosuppressive agents in PAH.
- Methotrexate and cardiovascular events
- Update on Systemic Sclerosis
- Therapeutische Strategien im Frühstadium der systemischen Sklerose
- Systemic and Localized Scleroderma in Children
- Therapeutisches Management akraler Manifestationen der systemischen Sklerose
- Consenso sobre Esclerodermia
- „Off label use“ von Methotrexat in der klinischen Rheumatologie
- Photochemotherapy for systemic sclerosis: effect on clinical and molecular markers
- An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.
- Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches.
- Evaluation of oral methotrexate in the treatment of systemic sclerosis
- Therapeutic options for systemic sclerosis.
Related papers
- Effect of alveolar volume on the interpretation of single breath DLCO.
- Increase of pulmonary diffusing capacity in systemic sclerosis.
- Isolated reduction in single-breath diffusion capacity in young, healthy, asymptomatic women.
- Endoscopic lung volume reduction with endobronchial valves in very low DLCO patients
- Measurements of membrane diffusing capacity and pulmonary capillary blood volume in normal subjects and patients with mild emphysema.
- DO WE REALLY NEED TO CORRECT FOR LUNG VOLUME WHEN INTERPRETING THE DIFFUSING CAPACITY
- CAN LUNG DIFFUSING CAPACITY FOR CARBON MONOXIDE PREDICT ECHOCARDIOGRAPHICALLY DIAGNOSED PULMONARY ARTERIAL HYPERTENSION
- Normal Predicted Values of Single-Breath Diffusing Capacity of the Lung in Healthy Nonsmoking Adults
- Normal Predicted Values of Pulmonary Carbon Monoxide Diffusing Capacity at Rest by Steady State Method for the Elderly Subjects